Shots:

• The P-III TOURMALINE-MM2 involves assessing of Ninlaro (ixazomib) + lenalidomide and dexamethasone vs PBO + lenalidomide and dexamethasone in 705 adult patients with newly diagnosed MM patients not eligible for autologous stem cell transplant
• Results: 13.5mos. increase in m-PFS (35.3 vs 21.8mos.); trial did not meet the threshold for statistical significance and 1Eps of PFS. In the prespecified expanded high-risk cytogenetics subgroup- m-PFS (23.8 vs 18.0mos.); rate of CR (26% vs 14%); m-TTP (45.8 vs 26.8mos.); m-OS not reached @ median follow up of (57.8 vs 58.6mos.)
• Ninlaro (ixazomib) is an oral proteasome inhibitor- being studies across the continuum of multiple myeloma treatment settings

­ Ref: Takeda | Image: Takeda